Leerink Partners Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective boosted by research analysts at Leerink Partners from $45.00 to $52.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners‘s price target suggests a potential upside of 24.77% from the company’s previous close.

A number of other research firms also recently weighed in on TEVA. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, September 4th. Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. HC Wainwright began coverage on shares of Teva Pharmaceutical Industries in a research report on Monday. They issued a “buy” rating and a $52.00 price objective on the stock. Finally, Barclays increased their target price on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an “overweight” rating in a report on Thursday, October 15th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $47.23.

Teva Pharmaceutical Industries Stock Down 0.4%

Shares of TEVA traded down $0.17 during midday trading on Thursday, hitting $41.68. The stock had a trading volume of 13,632,476 shares, compared to its average volume of 6,841,347. The company has a 50 day simple moving average of $39.32 and a two-hundred day simple moving average of $34.68. Teva Pharmaceutical Industries has a twelve month low of $23.61 and a twelve month high of $43.34. The firm has a market cap of $48.56 billion, a price-to-earnings ratio of 96.92, a price-to-earnings-growth ratio of 3.89 and a beta of 0.97. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.22% and a net margin of 2.94%. The company had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same period in the prior year, the firm earned $0.78 earnings per share. Teva Pharmaceutical Industries’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, analysts anticipate that Teva Pharmaceutical Industries will post 2.00 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Brian Savage sold 7,342 shares of the company’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the sale, the insider directly owned 8,500 shares of the company’s stock, valued at approximately $330,225. This represents a 46.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $39.06, for a total value of $14,358,456.00. The SEC filing for this sale provides additional information. 0.54% of the stock is owned by insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds have recently made changes to their positions in TEVA. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 2.2% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock valued at $1,384,216,000 after purchasing an additional 1,004,941 shares in the last quarter. WCM Investment Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 191.4% in the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after acquiring an additional 26,813,522 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Teva Pharmaceutical Industries by 5.8% in the 2nd quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock valued at $259,899,000 after acquiring an additional 419,329 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Teva Pharmaceutical Industries by 1.5% during the 1st quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock valued at $145,076,000 after acquiring an additional 72,880 shares during the period. Finally, Bessemer Group Inc. lifted its position in shares of Teva Pharmaceutical Industries by 1.6% during the 1st quarter. Bessemer Group Inc. now owns 4,350,483 shares of the company’s stock valued at $131,036,000 after acquiring an additional 70,058 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q3 beat and raised outlook: Teva reported adjusted earnings of $0.86 per share versus $0.72 expected, and revenue of $4.40 billion versus $4.23 billion expected. Strong branded-drug sales helped the company raise its 2026 revenue and product-sales outlook. Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: More optimistic analyst targets: TD Cowen raised its price target to $57 from $55 and kept a Buy rating. HC Wainwright also has a Buy rating, a $52 target, and forecasts 2027 EPS of $3.03. TD Cowen stock recommendations
• Positive Sentiment: Biosimilar portfolio expansion: Teva and Samsung Bioepis agreed to commercialize two FDA-approved biosimilars in the U.S., potentially adding products to Teva’s growth portfolio. Teva and Samsung Enter License and Commercialization Agreement
• Neutral Sentiment: Revenue remains a concern: Despite beating estimates, Q3 revenue declined 1.9% year over year, underscoring ongoing pressure even as the outlook improved. Teva stock: Q3 revenue slips as 2026 outlook rises
• Negative Sentiment: Clinical setback: Teva stopped its Phase 2 emrusolmin study after an interim review found insufficient efficacy. The company reported no safety concerns, but the decision removes a potential development opportunity. Why Is Teva Dropping a Drug Trial While Raising Its Outlook?

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.